A Systematic review of β-caryophyllene and Piperine as Multitarget Phytochemicals: Integrated Phytochemical Profiling and Mechanistic Insights into their Biological Activities
Fuente:
Zenodo
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Recurso digital |
| Publicado: |
Zenodo
2026
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1866902018744909824 |
|---|---|
| author | Prakash Sarwade1, Kavita Gaisamudre*2, Aditya Mishra3, Gaurav Chaudhary4, Omprakash Swami5, Akash Verma6, Saurabh Kumar Chauhan7 |
| author_facet | Prakash Sarwade1, Kavita Gaisamudre*2, Aditya Mishra3, Gaurav Chaudhary4, Omprakash Swami5, Akash Verma6, Saurabh Kumar Chauhan7 |
| contents | <p><span lang="EN-US">β-Caryophyllene, a dietary sesquiterpene and selective CB2 receptor agonist, and piperine (PIP), a bioavailability-enhancing alkaloid, represent two potent phytochemicals with extensive, complementary biological activities. This systematic review synthesizes the current scientific evidence on their integrated phytochemical profiling, pharmacokinetics, and pharmacological properties, with a focus on their synergistic potential as a multitarget therapeutic combination. Rigorous analysis confirms that BCP exhibits pronounced anti-inflammatory, antioxidant, analgesic, and cytoprotective effects, largely mediated through CB2 activation and Nrf2 pathway induction. PIP, beyond its intrinsic pharmacological merits, acts as a potent bioenhancer by inhibiting drug-metabolizing enzymes (CYP450, UGT) and efflux transporters (P-glycoprotein). Critically, co-administration demonstrates a dual synergy: pharmacokinetically, PIP significantly enhances the oral bioavailability and systemic exposure of BCP; pharmacodynamically, their actions converge on shared pathways (e.g., NF-κB inhibition, Nrf2 activation), yielding superior efficacy in preclinical models of neuropathic pain, neurodegeneration, metabolic syndrome, and hepatotoxicity compared to monotherapies. This synergy enables dose-sparing effects </span><span lang="EN-US">and an improved therapeutic index. The findings underscore the BCP-PIP pair as a paradigm of natural product synergy, transitioning from traditional spice constituents to a promising, evidence-based multitarget strategy for managing complex chronic diseases. However, clinical translation requires standardized formulations and rigorous human trials to validate safety and efficacy.</span></p> <p><span lang="EN-US"> </span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_18231812 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | A Systematic review of β-caryophyllene and Piperine as Multitarget Phytochemicals: Integrated Phytochemical Profiling and Mechanistic Insights into their Biological Activities Prakash Sarwade1, Kavita Gaisamudre*2, Aditya Mishra3, Gaurav Chaudhary4, Omprakash Swami5, Akash Verma6, Saurabh Kumar Chauhan7 β-Caryophyllene, Piperine, Phytochemical synergy, Bioavailability enhancement, Cannabinoid receptor type 2 (CB2) <p><span lang="EN-US">β-Caryophyllene, a dietary sesquiterpene and selective CB2 receptor agonist, and piperine (PIP), a bioavailability-enhancing alkaloid, represent two potent phytochemicals with extensive, complementary biological activities. This systematic review synthesizes the current scientific evidence on their integrated phytochemical profiling, pharmacokinetics, and pharmacological properties, with a focus on their synergistic potential as a multitarget therapeutic combination. Rigorous analysis confirms that BCP exhibits pronounced anti-inflammatory, antioxidant, analgesic, and cytoprotective effects, largely mediated through CB2 activation and Nrf2 pathway induction. PIP, beyond its intrinsic pharmacological merits, acts as a potent bioenhancer by inhibiting drug-metabolizing enzymes (CYP450, UGT) and efflux transporters (P-glycoprotein). Critically, co-administration demonstrates a dual synergy: pharmacokinetically, PIP significantly enhances the oral bioavailability and systemic exposure of BCP; pharmacodynamically, their actions converge on shared pathways (e.g., NF-κB inhibition, Nrf2 activation), yielding superior efficacy in preclinical models of neuropathic pain, neurodegeneration, metabolic syndrome, and hepatotoxicity compared to monotherapies. This synergy enables dose-sparing effects </span><span lang="EN-US">and an improved therapeutic index. The findings underscore the BCP-PIP pair as a paradigm of natural product synergy, transitioning from traditional spice constituents to a promising, evidence-based multitarget strategy for managing complex chronic diseases. However, clinical translation requires standardized formulations and rigorous human trials to validate safety and efficacy.</span></p> <p><span lang="EN-US"> </span></p> |
| title | A Systematic review of β-caryophyllene and Piperine as Multitarget Phytochemicals: Integrated Phytochemical Profiling and Mechanistic Insights into their Biological Activities |
| topic | β-Caryophyllene, Piperine, Phytochemical synergy, Bioavailability enhancement, Cannabinoid receptor type 2 (CB2) |
| url | https://doi.org/10.5281/zenodo.18231812 |